Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

(487) - - - (487)

Income before income taxes 652 - (2) 96 746

Income tax expense 87 - - - 87

Net income $565 $ - $(2) $96 $659

Preferred stock dividends 22 - - - 22

Net income available to

common shareholders $543 $ - $(2) $96 $637

Diluted earnings per

common share $0.36 $0.42

Average common shares

outstanding-diluted 1,571 1,571

SCHERING-PLOUGH CORPORATION

Reconciliation from Reported Net Income Available to Common Shareholders and Reported Diluted Earnings Per Common Share to As Reconciled Amounts for Net Income

Available to Common Shareholders and Diluted Earnings per Common Share

(Amounts in Millions)

"As Reconciled" amounts related to net income available to common shareholders and diluted earnings per common share reflect the following adjustments:

First Quarter

(unaudited)

2008 2007

Purchase accounting adjustments:

Amortization of intangibles in connection

with the acquisition of Organon

BioSciences (a) $132 $-

Depreciation related to the fair value

adjustment of fixed assets related to the

acquisition of Organon BioSciences (b) 8 -

Charge related to the fair value adjustment

to inventory related to the acquisition of

Organon BioSciences (a) 551 -

Total purchase accounting
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 26, 2015 Global Stem Cells ... plans for the company’s first cellular and regenerative medicine ... a full day, hands-on stem cell training class Oct. ... Garcia Gimenez, M.D., President of Therapeutic Confrontations (CONFTERA) in ... increasing interest in regenerative medicine and recent advances in ...
(Date:5/26/2015)... Texas , May 26, 2015  A simple ... Health Science Center to detect early Alzheimer,s disease is ... adults. Detailed standardized guidelines that are needed ... have been published in Alzheimer,s & Dementia . ... of an international working group that includes UNT Health ...
(Date:5/26/2015)... mája 2015 Kevin Xu , ... prezidentom Barackovi Obamovi a Billovi Clintonovi za ich ... Dr. Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník ... v oblasti vedy a príkladné vedenie svojej komunity ...
(Date:5/26/2015)... 26, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... study protocol for the company,s Phase IIb trial of ... and Drug Administration (FDA). The submission was made under ... The Phase IIb study of ORMD-0801 for type ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... Therapeutics,(Nasdaq: NKTR ) today announced that ... pulmonary delivery assets, technology, and intellectual,property to Novartis ... completed,on December 31, 2008. , ... certain dry powder and,liquid pulmonary formulation and manufacturing ...
... to announce the 3rd Global Jatropha Hi-Tech Agricultural Training Programme ... privilege to provide most authoritative Knowledge platform known as Global ... Jatropha Oil Crop Projects, Programmes and Priorities to Feed Biodiesel ... ...
... Merial, a world leading animal health,company, and the ... Merial to obtain exclusive rights to Imugene vector,technology. ... the product development process to global sales. Additional ... and, if successful, will,also progress into the product ...
Cached Biology Technology:Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million 2CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 2CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 3CJP Declares the Dates of 3rd Global Jatropha Hi-Tech Agricultural Training Programme 4Imugene and Merial Establish Strategic Alliance 2
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint Cards ... FPC1025 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... be used by smartphone manufacturers in China ... the communicated revenue guidance of + 1 000 MSEK for 2015. ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a ... established helmet producer, announced today that they will expand ... the world,s first bio-sensing cycling helmet and the first ... in two new colors in order to give cyclists ... product. In addition, LifeBEAM and Lazer announced their plan ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... University School of Medicine has helped confirm the reliability ... ushering in the long-promised era of personalized medicine based ... one of the five sites that helped determine that ... risk of developing cirrhosis from chronic hepatitis C infection. ...
... hospitals in Peru has shown that opening windows and ... ventilated negative-pressure rooms and 18 times that of rooms ... led by Rod Escombe from Imperial College London, compared ... as respiratory isolation rooms, TB wards, respiratory wards, general ...
... called lupus, is a complex autoimmune disease marked ... depression, among other symptoms. Some studies have described ... manifestation, psychosis, and a protein autoantibody associated with ... , To investigate how an autoantibody could stimulate ...
Cached Biology News:New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3New insights into autoimmunity and depression 2
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
Adult Bovine Serum US Origin...
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 13(S)-HODE is produced by incubation of linoleic acid ... shown to inhibit the adhesion of tumor cells ...
Biology Products: